Effect of turosteride, a 5α-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma

Prostate

Volumn 30, Issue 2, 1997, Pages 85-91

  Zaccheo, T ^a,b   Giudici, D ^a   Di Salle, E ^a  

^a Dept Endocrinol R D Oncol P   (Italy)

^b Defpt of Endocrinology Pharmacia   (Italy)

Author keywords

androgen levels; FCE 26073; flutamide; leuprolide

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TUROSTERIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; CASTRATION; CONTROLLED STUDY; DRUG MIXTURE; HORMONE BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; FLUTAMIDE; LEUPROLIDE; LUTEINIZING HORMONE; MALE; ORGAN SIZE; PITUITARY GLAND, ANTERIOR; PROSTATE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; SEMINAL VESICLES; TESTIS; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031019858     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970201)30:2<85::AID-PROS3>3.0.CO;2-J     Document Type: Article

References (21)

1. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R3327-H adenocarcinoma. Cancer Res 41:5070-5075, 1981.
2. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, Mc Loughlin MG: Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab 67:806-816, 1988.
3. di Salle E, Briatico G, Giudici D, Ornati G, Nesi M, Panzeri A: 17β-Acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5α-reductase. J Steroid Biochem Mol Biol 41:765-768, 1992.
4. di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A: Endocrine properties of the testosterone 5α-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol 48:241-248, 1994.
5. di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A: Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol 46:549-555, 1993.
6. Geran RI, Greenberg NH, Mc Donald MM, Schumacher AM, Abbott BJ: Protocol for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1-103, 1972.
7. Vogelzang NJ, Kennealey GT: Recent developments in endocrine treatment of prostate cancer. Cancer 70:966-976, 1992.
8. Hsieh W-S, Simons JW: Systemic therapy of prostate cancer. New concepts from prostate cancer rumor biology. Cancer Treatment Rev 19:229-260, 1993.
9. Brooks JR, Berman C, Primka RL, Reynolds GF, Rasmusson GH: 5α-Reductase inhibitory and antiandrogenic activities of some 4-azasteroids in the rat. Steroids 47:1-19, 1986.
10. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Brachen BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191, 1992.
11. Stoner E: The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 37: 375-378, 1990.
12. Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH, Slater EE: Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R3327. Prostate 18:215-227, 1991.
13. Lamb JC, Levy MA, Johnson RK, Isaacs JT: Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SKF 105657. Prostate 21:15-34, 1992.
14. Ghusn H, Shao TC, Klima M, Cunninghamm GR: 4-MAPC, a 5α-reductase inhibitor, reduces rat ventral prostate weight, DNA and prostatein concentrations. J Androl 12:315-322, 1991.
15. Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB: Differential effect of 5α-reductase inhibition and castration on androgen regulated gene expression in rat prostate. Mol Endocrinol 5:1023-1029, 1991.
16. Shao TC, Kong A, Cunningham GR: Effects of finasteride on the rat ventral prostate. J Androl 14:79-86, 1993.
17. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed cell death of normal and malignant prostatic cells. J Androl 13:457-464, 1992.
18. Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 87:3640-3644, 1990.
19. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD: Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 152:433-437, 1994.
20. Liao SS, Kokontis J, Sai T, Hiipakka RA: Androgen receptors: Structures, mutations, antibodies and cellular dynamics. J Steroid Biochem 34:41-45, 1989.
21. Ford LG, Brawley OW, Perlman JA, Nayfield SG, Johnson KA, Kramer BS: The potential for hormonal prevention trials. Cancer 74:2726-2733, 1994.